Business
Why the Telix (ASX:TLX) share price is surging 8%
Telix Pharmaceuticals Ltd (ASX: TLX) shares are rocketing higher this morning after the company announced the United States Food and Drug Administration (FDA) approved its new drug application (NDA) for a prostate cancer imaging product. In early morning trade, the Telix share price is trading 8.1% higher at $3.07.
NDA approval
Investors are driving up the Telix share price today after news that the FDA has accepted the company’s NDA for TLX591-CDx (kit for the preparation of Ga-PSMA-11). The prostate cancer imaging product is a radiopharmaceutical targeting Prostate-Specific Membrane Antigen (PSMA). It uses a Positron Emission Tomography (PET) to scan for the disease.
Telix’s NDA submission for its prostate cancer imaging…
-
General21 hours agoForget a tariff-induced recession, Australians have been in recession for two years
-
Noosa News22 hours agoQueensland Opposition accuses government of ‘covering up’ Callide Power Station explosion
-
Noosa News21 hours agoMan dies after slamming stolen car into another vehicle on rural Queensland highway
-
Noosa News23 hours agoCameron Hunt assisting police with inquiries after his wife is found dead in suspicious Geham house fire outside of Toowoomba